Published in J Natl Cancer Inst on February 09, 2010
Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol (2013) 1.92
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer (2011) 1.36
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol (2011) 1.35
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
Ras and Raf pathways in epidermis development and carcinogenesis. Br J Cancer (2010) 0.93
Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn (2011) 0.89
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81
Proposed FDA rules on painkillers in U.S. Rile cancer community. J Natl Cancer Inst (2009) 1.41
Epigenetics: Unravelling the cancer code. Nature (2011) 1.02
Approval of provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst (2010) 1.02
NCI-MATCH pairs tumor mutations with matching drugs. Nat Biotechnol (2015) 0.99
Breast density legislation fueling controversy. J Natl Cancer Inst (2013) 0.95
Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst (2008) 0.94
Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst (2003) 0.93
A second chance for hormone replacement therapy? EMBO Rep (2003) 0.93
Breast density gains acceptance as breast cancer risk factor. J Natl Cancer Inst (2010) 0.92
RNA interference advances to early-stage clinical trials. J Natl Cancer Inst (2010) 0.91
Homing in on mechanisms linking breast density to breast cancer risk. J Natl Cancer Inst (2010) 0.90
FDA considers restricting or banning laparoscopic morcellation. J Natl Cancer Inst (2014) 0.90
Biomarkers: Portents of malignancy. Nature (2011) 0.90
Biotech industry tries to recover from 2-year lull. J Natl Cancer Inst (2003) 0.89
Analyse this. EMBO Rep (2003) 0.88
Is nanotechnology ready for primetime? J Natl Cancer Inst (2006) 0.88
The squeaky wheel gets the grease. Research funding is not necessarily allocated to those who need it most. EMBO Rep (2005) 0.88
Feeding the flame: new research adds to role of inflammation in cancer development. J Natl Cancer Inst (2005) 0.87
Genomics and health care. How genomics medicine is translated into better health care largely depends on how physicians handle this information. EMBO Rep (2004) 0.87
Anti-PD-L1 antibody active in metastatic bladder cancer. Lancet Oncol (2014) 0.86
Back to nature: extinction of medicinal plants threatens drug discovery. J Natl Cancer Inst (2008) 0.85
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. J Natl Cancer Inst (2009) 0.85
Food and Drug Administration responds to pressure for expanded drug access. J Natl Cancer Inst (2014) 0.84
FDA to regulate direct-to-consumer genetic tests. J Natl Cancer Inst (2010) 0.83
Harnessing the immune system to battle Alzheimer's: some of the most promising approaches to fight Alzheimer's disease aim to develop vaccines. EMBO Rep (2002) 0.83
AIDS-related cancers increase in Africa. J Natl Cancer Inst (2011) 0.83
Going global in R&D. EMBO Rep (2004) 0.83
Macrophages: cancer therapy's double-edged sword. J Natl Cancer Inst (2012) 0.82
List of 'prurient' research stirs fear, anger among US scientists. Nat Med (2004) 0.82
Health is a global issue. EMBO Rep (2003) 0.82
Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer. J Natl Cancer Inst (2013) 0.82
The ethics of innovation. Should innovative surgery be exempt from clinical trials and regulations? EMBO Rep (2003) 0.81
Illuminating the diabetes-cancer link. J Natl Cancer Inst (2012) 0.81
Search and destroy: recent research exploits adult stem cells' attraction to cancer. J Natl Cancer Inst (2005) 0.81
Search for new treatments intensifies for triple-negative breast cancer. J Natl Cancer Inst (2009) 0.80
American Society of Clinical Oncology Developing First Clinical Trial. J Natl Cancer Inst (2015) 0.80
Loosening addiction's deadly grip. Recent research paints a picture of addiction as a progressive, chronic neurological disease that wreaks havoc with brain chemistry. EMBO Rep (2006) 0.80
Antiangiogenesis research is booming, as questions and studies proliferate. J Natl Cancer Inst (2009) 0.80
Fighting fat. New drugs against obesity in the pipeline. EMBO Rep (2002) 0.80
Genomic research advances pancreatic cancer's early detection and treatment. J Natl Cancer Inst (2015) 0.79
European boost for particle therapy. Nature (2009) 0.79
Cancer disparities: disentangling the effects of race and genetics. J Natl Cancer Inst (2008) 0.79
Watchful waiting beats androgen deprivation therapy in early prostate cancer. J Natl Cancer Inst (2008) 0.79
Cancer gene therapy steadily advances. J Natl Cancer Inst (2008) 0.79
Telomerase-based therapies emerging slowly. J Natl Cancer Inst (2010) 0.79
Cell cycle inhibitors make progress. J Natl Cancer Inst (2014) 0.79
Evidence accumulating that depression may hinder survival. J Natl Cancer Inst (2014) 0.79
Ibrutinib promising in subtype of DLBCL. Lancet Oncol (2015) 0.79
BioTime acquires Geron's stem cell program. Nat Biotechnol (2013) 0.79
Accidental passengers or perpetrators? Current virus-cancer research. J Natl Cancer Inst (2004) 0.79
An apple a day may be safer than vitamins. J Natl Cancer Inst (2008) 0.78
New approaches tackle rising pancreatic cancer rates. J Natl Cancer Inst (2014) 0.78
World Health Organization focuses on antitobacco efforts in developing nations through treaty. J Natl Cancer Inst (2006) 0.78
Researchers tackle metastasis, cancer's last frontier. J Natl Cancer Inst (2007) 0.78
Researchers attempting to define role of cytokines in cancer risk. J Natl Cancer Inst (2005) 0.78
US bioethics commission promises policy action. Nature (2009) 0.77
Developing nations face challenges as breast cancer rises. J Natl Cancer Inst (2011) 0.77
Carbon ion therapy to debut in Europe. J Natl Cancer Inst (2009) 0.77
Tracking chemotherapy's effects on secondary cancers. J Natl Cancer Inst (2013) 0.77
The cutting edge in surgery. Telesurgery has been shown to be feasible--now it has to be made economically viable. EMBO Rep (2002) 0.77
Targeted Therapies Improve Outlook for Chronic Lymphocytic Leukemia. J Natl Cancer Inst (2015) 0.77
Cancer-killing viruses assist gene therapies. J Natl Cancer Inst (2008) 0.77
A nutraceutical a day may keep the doctor away. Consumers are turning increasingly to food supplements to improve well-being when pharmaceuticals fail. EMBO Rep (2005) 0.77
New effort seeks to unravel the mystery of undiagnosed disease. Nat Med (2008) 0.77
Early-stage progress on glioma vaccines. J Natl Cancer Inst (2011) 0.77
Erythropoietin may impair, not improve, cancer survival. Nat Med (2003) 0.77
Variability is its specialty. Influenza vaccine shortages and the spectre of an avian influenza epidemic. EMBO Rep (2005) 0.77
Clues emerge on how HIV increases lymphoma risk. J Natl Cancer Inst (2010) 0.77
New pain drugs in pipeline, but challenges to usage remain. J Natl Cancer Inst (2012) 0.77
Is health only skin-deep? Do advances in genomics mandate racial profiling in medicine? EMBO Rep (2002) 0.77
MRI study identifies three subtypes of glioblastoma. Lancet Oncol (2015) 0.77
When the immune system goes on the attack. EMBO Rep (2004) 0.76
Fast tracking drugs to patients. Drug approval agencies are frequently criticised for either being too slow or too fast. EMBO Rep (2002) 0.76
When mind meets machine. EMBO Rep (2005) 0.76
Ovarian cancer genome sequencing unveils findings. J Natl Cancer Inst (2011) 0.76
Anti-PD-L1 inhibitor durvalumab in bladder cancer. Lancet Oncol (2016) 0.76
Checkpoint blockade immunotherapy for cancer comes of age. J Natl Cancer Inst (2015) 0.76
Less is more. EMBO Rep (2003) 0.76
Mind-body research moves towards the mainstream. EMBO Rep (2006) 0.76
Tasquinimod treatment for prostate cancer. Lancet Oncol (2016) 0.76
Adjuvant trastuzumab improves survival in early breast cancer. Lancet Oncol (2014) 0.76
Combination immunotherapy breakthrough for melanoma. Lancet Oncol (2015) 0.76
FDA likely to further restrict or ban morcellation. Lancet Oncol (2014) 0.76
Evidence of efficacy: researchers investigating markers for angiogenesis inhibitors. J Natl Cancer Inst (2003) 0.76
Venetoclax targets BCL2 in chronic lymphocytic leukaemia. Lancet Oncol (2015) 0.76
Biotechnology to fight bioterrorism. While the fight against terrorism is helping to revitalize the biotech market, academic scientists are starting to worry about limitations on research. EMBO Rep (2003) 0.75
Connecting viruses to cancer: how research moves from association to causation. J Natl Cancer Inst (2004) 0.75
A live issue and a moving target. EMBO Rep (2003) 0.75
Like a snake in the grass. EMBO Rep (2004) 0.75
Beyond FDG: Many Molecular Imaging Agents Are in Development. J Natl Cancer Inst (2010) 0.75
New superbug or tempest in a teapot? EMBO Rep (2005) 0.75
Looking for the trigger. The Environmental Genome Project to uncover the interactions of genes and the environment in disease. EMBO Rep (2003) 0.75
Gulf War syndrome revisited. EMBO Rep (2003) 0.75
New initiatives aim to test more cancer drugs for children. J Natl Cancer Inst (2004) 0.75
Lenalidomide maintenance for multiple myeloma. Lancet Oncol (2012) 0.75
US court reverses gene patent ruling for BRCA1 and BRCA2. Lancet Oncol (2011) 0.75
Large variations seen in treatment of adults with brain cancer. J Natl Cancer Inst (2005) 0.75
Puerto Rican government offers support for country's cancer center. J Natl Cancer Inst (2004) 0.75
Improving the outlook for myelodysplastic syndrome. J Natl Cancer Inst (2012) 0.75
Room of its own. EMBO Rep (2004) 0.75